Glenmark Pharmaceuticals has introduced its new semaglutide brand, GLIPIQ, in India at a significantly lower price point, aiming to expand access to advanced diabetes treatments and challenge existing premium products in the market.
Glenmark Pharmaceuticals’ new semaglutide brand GLIPIQ has entered India’s diabetes market with a clear message: price and access will be the battleground. According to the company’s announcement, the weekly treatment is now available in vial and pre-filled pen formats, with dosing starting at ₹325. Glenmark says the launch is intended to make GLP-1 therapy, a class of medicines used to improve blood-sugar control and reduce appetite, more affordable for patients with type 2 diabetes.
For now, the medicine is being positioned strictly for type 2 diabetes mellitus, not obesity management. That distinction matters because semaglutide has gained global attention in both diabetes and weight-loss care, but Glenmark’s Indian launch materials and independent summaries of the product describe GLIPIQ as a diabetes treatment approved by Indian regulators in March 2026. Any extension into obesity would require a separate regulatory and commercial strategy, and there is no sign in the available material that such a move has been announced.
The market opportunity, however, is substantial. India is widely estimated to have around 77 million people living with type 2 diabetes, and many remain untreated or undertreated because newer therapies can be too expensive for broad use. In that context, GLIPIQ’s pricing is likely to put pressure on other GLP-1 providers, particularly branded products that have relied on premium pricing and physician loyalty. Pharma India Magazine and Economic Times’ pharma coverage both reported that Glenmark’s weekly price band of ₹325 to ₹440, depending on formulation, is meant to widen access and lower the cost barrier that has limited uptake of advanced diabetes medicines.
The competitive effect will depend on how fast doctors adopt the product and how patients respond to the lower-cost vial and pen options. Glenmark is also backing the launch with its “Sankalp” patient support programme, which it says is designed to help people start therapy and stay on treatment. That combination of price, format choice and support could allow the company to win share in a segment that has so far been constrained by affordability, while forcing rivals to reconsider their own pricing and patient-access strategies.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
